Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $451.63 -1.6%
Revenue Growth %: +8.4%
Financial Fact:
Sales, general and administrative expenses: 106.06M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +8.4%
Financial Fact:
Sales, general and administrative expenses: 106.06M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of $11.85 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
- Wall Street scrambles to lift Micron price targets ahead of earnings
- JPMorgan Upgrades Visteon (VC) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
